TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00936390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist (antagonist) therapy
Description: LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Dose-Escalated Radiation Therapy
Description: External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-Escalated Radiation Therapy
Description: External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
Study: NCT04055948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one teaching sessions
Description: One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 \& 3 delivered by phone during COVID-19)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone booster contact
Description: Telephone booster contact 2 weeks post-treatment.
Study: NCT02038673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral
Study: NCT00918632

Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> C -\> B. Each of these treatments will be separated by a 7 day washout period.

Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> C -\> A. Each of these treatments will be separated by a 7 day washout period.

Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> A -\> C. Each of these treatments will be separated by a 7 day washout period.
Study: NCT02094352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Infusion + Epidural Infusion
Description: The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
Study: NCT00918632

Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> A -\> B. Each of these treatments will be separated by a 7 day washout period.
Study: NCT02038673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral
Study: NCT00918632

Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> B -\> A. Each of these treatments will be separated by a 7 day washout period.
Study: NCT02094352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group + Epidural infusion
Description: The saline and epidural infusions will be administered over 96 hours with appropriate titration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Booster Infusion
Description: Patients will receive three ketamine booster infusions over the course of three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group Booster Infusion
Description: Patients will receive three saline booster infusions over the course of three months.
Study: NCT03558425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT02857725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987517
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT04100980

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT01946620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform
Study: NCT01946620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Study: NCT01058642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02038673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral
Study: NCT04201548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training
Description: These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long High Intensity Interval Training
Description: The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short High Intensity Interval Training
Description: The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050
Study: NCT02023385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-9000 LLLT
Description: Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham BTL-9000 LLLT
Description: Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
Study: NCT02917616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkaline drinking-water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral drinking-water
Study: NCT05006183

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention with Drug-Eluting Stents

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous coronary intervention with Drug-Eluting Stents
Study: NCT00566098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MILs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Study: NCT02023502

Intervention type: OTHER
Intervention: collection of urine and blood sample

Intervention type: OTHER
Intervention: collection of urine and blood sample
Study: NCT01676584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6811135
Description: single ascending doses sc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single doses sc
Study: NCT03183271

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam proton radiation therapy.
Description: Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
Study: NCT04137991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nol-Index guided analgesia
Description: Monitor that indicates the level of nociception-antinociception balance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Analgesia
Description: Administration of remifentanil based guided by heart rate, blood pressure, and experience
Study: NCT02122159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE Cellular Therapy
Description: A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
Study: NCT00475852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: 0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
Study: NCT01197222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoClear Lens Cleaning Device
Description: EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
Study: NCT04295564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional 2 weeks of CPAP
Description: Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
Study: NCT01973127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verum rTMS
Description: rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
Study: NCT02699177

Intervention type: DEVICE
Intervention: CBF measurements
Description: CBF measurements

Intervention type: DEVICE
Intervention: CBF measurements
Description: CBF measurements
Study: NCT02654080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 nef/tat/vif, env pDNA vaccine
Description: 1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV HIV envC vaccine
Description: 1 × 10\^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated).
Study: NCT03036722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control porridge
Description: control porridge matched for energy and fat content.
Study: NCT03984734

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatoduodenectomy with antrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreatoduodenectomy
Study: NCT00104845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human gp100 plasmid DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human gp100 plasmid DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse gp100 plasmid DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse gp100 plasmid DNA vaccine
Study: NCT01879735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-CSar
Description: PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-CSar
Description: PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
Study: NCT04643496

Intervention type: PROCEDURE
Intervention: Laparoscopic or open Ileocolic resection
Description: Laparoscopic or open Ileocolic resection
Study: NCT01058642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study: NCT01286467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
Study: NCT04114929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Threshold-based Training
Description: Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
Study: NCT00514215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Days 1 \& 32
Study: NCT02848508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT01032681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 521873
Description: Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 521873
Description: Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 521873
Description: Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle
Study: NCT03574883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
Study: NCT01170260

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)
Description: Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)
Description: Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION
Description: Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
Study: NCT02614703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy using Acetic Acid 2.5%
Description: Spraying esophageal mucosa during random biopsies for Barrett's esophagus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard random esophageal biopsies
Description: Random esophageal biopsies performed as per protocol
Study: NCT02931565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olinciguat
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: oral tablet